{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 539862f0-64ef-457f-92aa-a77aa8171387 --><h2>Update</h2><!-- end field 539862f0-64ef-457f-92aa-a77aa8171387 -->","summary":null,"htmlStringContent":"<!-- begin item 9ee32562-e1cd-45b9-b615-1f8610482724 --><!-- end item 9ee32562-e1cd-45b9-b615-1f8610482724 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"7c5c6228-6a7e-5ead-8be6-a9295dbbd17b","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 3cd29adf-41bb-40e4-ae9e-85b984edfdf6 --><h3>New evidence</h3><!-- end field 3cd29adf-41bb-40e4-ae9e-85b984edfdf6 -->","summary":null,"htmlStringContent":"<!-- begin item 31eb01c8-639a-4b80-b475-4d57305552dd --><!-- begin field 74fa4ca3-47b0-4bef-ad83-a870ba05a893 --><h3>Evidence-based guidelines</h3><!-- end field 74fa4ca3-47b0-4bef-ad83-a870ba05a893 --><!-- begin field c5952941-436b-4a5e-ab0f-3f536b7db628 --><ul><li>DTB Team (2020) Can a point-of-care CRP test reduce antibiotic use in COPD? Drug and Therapeutics Bulletin. <a href=\"https://dtb.bmj.com/\" data-hyperlink-id=\"1fd10e01-59a1-4cbf-8e20-ab8800977ef5\">www.dtb.bmj.com</a> [<a href=\"https://dtb.bmj.com/content/early/2020/03/11/dtb.2020.000016\" data-hyperlink-id=\"49176b33-6ecc-47bd-bb0a-ab8800977f14\">Abstract</a>]Â </li></ul><!-- end field c5952941-436b-4a5e-ab0f-3f536b7db628 --><!-- begin field 34efe389-d50f-45d5-b95b-7194fb0270ae --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 34efe389-d50f-45d5-b95b-7194fb0270ae --><!-- begin field c705d861-1392-455e-bc8e-cde47b2ca8d8 --><p>No new technology appraisals published since 1 August 2019.</p><!-- end field c705d861-1392-455e-bc8e-cde47b2ca8d8 --><!-- begin field f3ab9519-9675-4871-b523-3d904c265082 --><h3>Economic appraisals</h3><!-- end field f3ab9519-9675-4871-b523-3d904c265082 --><!-- begin field c63f2d94-059b-4672-96c0-141944d66944 --><p>No new economic appraisals relevant to England since 1 August 2019.</p><!-- end field c63f2d94-059b-4672-96c0-141944d66944 --><!-- begin field 22d3cec5-3e25-408e-8d4f-9c6adde04ead --><h3>Systematic reviews and meta-analyses</h3><!-- end field 22d3cec5-3e25-408e-8d4f-9c6adde04ead --><!-- begin field eadab6ae-dbae-4aad-be35-ce41e39ef3d5 --><p>No new systematic reviews or meta-analyses since 1 August 2019.</p><!-- end field eadab6ae-dbae-4aad-be35-ce41e39ef3d5 --><!-- begin field e2ca3c83-2b0c-44eb-9b12-f9b19cbf74b7 --><h3>Primary evidence</h3><!-- end field e2ca3c83-2b0c-44eb-9b12-f9b19cbf74b7 --><!-- begin field 5c938636-3e97-4c90-bcfa-b1cbabb3f0e8 --><ul><li>Janknegt, R., Kooistra, J., Metting, E., Dekhuijzen, R. (2020)<em> Rational selection of inhalation devices in the treatment of chronic obstructive pulmonary disease by means of the System of Objectified Judgement Analysis (SOJA). </em>European Journal of Hospital Pharmacy. <a href=\"https://ejhp.bmj.com/\" data-hyperlink-id=\"41dc83da-1176-4973-98e2-ac3d00afe4a0\">www.ejhp.bmj.com</a> [<a href=\"https://ejhp.bmj.com/content/early/2020/09/12/ejhpharm-2020-002229\" data-hyperlink-id=\"d5373622-f740-474b-ba23-ac3d00afe4c0\">Abstract</a>]</li><li>Janjua, S., Fortescue, R., Poole, P. (2020) <em>Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.</em> Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"4d455ac6-d675-407a-a5de-ac3d00b1ef76\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002309.pub6/full\" data-hyperlink-id=\"ed0f1e0f-c0ea-4d05-ac88-ac3d00b1f05a\">Free Full-text</a>]</li></ul><!-- end field 5c938636-3e97-4c90-bcfa-b1cbabb3f0e8 --><!-- end item 31eb01c8-639a-4b80-b475-4d57305552dd -->","subChapters":[]},{"id":"d90812f6-c820-5551-96cd-9fb54ab3c890","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 016b1f61-263b-4989-8a76-3a00291853f6 --><h3>New policies</h3><!-- end field 016b1f61-263b-4989-8a76-3a00291853f6 -->","summary":null,"htmlStringContent":"<!-- begin item 57ba09a2-3b8d-40ca-b5d7-42e6914d0ca9 --><!-- begin field 508c094c-8fd5-4e14-8852-cd7aa713c136 --><p>No new national policies or guidelines since 1 August 2019.</p><!-- end field 508c094c-8fd5-4e14-8852-cd7aa713c136 --><!-- end item 57ba09a2-3b8d-40ca-b5d7-42e6914d0ca9 -->","subChapters":[]},{"id":"1c27b7ae-e078-542d-8c24-aa54c5a2ca46","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 4d0509bf-a162-48d7-a142-4a2df7221a2a --><h3>New safety alerts</h3><!-- end field 4d0509bf-a162-48d7-a142-4a2df7221a2a -->","summary":null,"htmlStringContent":"<!-- begin item 3a565da1-8722-47db-a024-c4dc8a470ed3 --><!-- begin field d27ad55f-ad88-48e7-b812-aa5959ccea9f --><p>No new safety alerts issued since 1 August 2019.</p><!-- end field d27ad55f-ad88-48e7-b812-aa5959ccea9f --><!-- end item 3a565da1-8722-47db-a024-c4dc8a470ed3 -->","subChapters":[]},{"id":"67e858e2-d3ce-5664-83c4-a231eac06e2c","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field f8e1f956-bc85-45eb-9de5-51922dedb103 --><h3>Changes in product availability</h3><!-- end field f8e1f956-bc85-45eb-9de5-51922dedb103 -->","summary":null,"htmlStringContent":"<!-- begin item 42a49448-f862-4e01-bfae-248b22592c13 --><!-- begin field 0be4944b-5ad2-4e04-8c74-9cb3a4f53cf9 --><ul><li>Mucolight (acetylcysteine) 600 mg tablets are a mucolytic agent licensed for the adjunctive therapy of respiratory tract disorders characterized by excessive, viscous mucus, including chronic obstructive airways disease. See more <a href=\"https://www.medicines.org.uk/emc/product/11366/smpc\" data-hyperlink-id=\"2cb59a1f-e593-4d40-9195-abed00bdcb14\">here</a>.</li><li>Bevespi Aerosphere is licensed as maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. See more <a href=\"https://www.medicines.org.uk/emc/product/12024/smpc\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"e7a8323c-c741-47a0-9213-acbf00f212de\">here</a>.</li><li>Trixeo Aerosphere is licensed as maintenance treatment in adults with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of inhaled corticosteroid and long-acting beta-2-agonist or combination of long-acting beta-2-agonist and long-acting muscarinic antagonist. See more <a href=\"https://www.medicines.org.uk/emc/product/12028/smpc\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"75597b76-6dc0-479e-ac4f-acbf00f212de\">here</a>.</li></ul><!-- end field 0be4944b-5ad2-4e04-8c74-9cb3a4f53cf9 --><!-- end item 42a49448-f862-4e01-bfae-248b22592c13 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}